Adjuvant WIDER
Purpose
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer–free survival, in a close-to-clinical practice patient population with HR-positive (HR+), HER2-negative (HER2−), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
For more information please visit https://clinicaltrials.gov/study/NCT05827081?term=CLEE011O12001
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671 .
Share
